New tuberculosis research movement needed

In this week's PLoS Medicine, Christian Lienhardt from the WHO in Geneva, Switzerland and colleagues announce that the Stop TB Partnership and the WHO Stop TB Department have launched the TB Research Movement.

Read More →

The influence of TB treatment on efavirenz clearance in patients co-infected with HIV and TB

Concomitant rifampicin-containing tuberculosis treatment reduced apparent efavirenz clearance with a corresponding increase in efavirenz exposure.

Read More →

The Global Fund Board cancels Round 11 and introduces tough new rules for grant renewals

Financial difficulties have caused the Global Fund Board to cancel Round 11. This difficult decision was made at a stressful two-day Board meeting just concluded in Accra, Ghana. The Board also announced new rules for grant renewals in an attempt to find savings that can be applied to funding new proposals.

Read More →

No political will to support generic medication

South African health experts are calling on governments to use legally available mechanisms to promote the production or import of generic drugs in their countries.

Read More →

Time of great change in TB drug development

We are living in a time of great change and excitement in TB drug development. The last year has witnessed a number of epochal changes, including the approval and rollout of the most rapid test for TB ever discovered, the GeneXpert; the combination TB drug studies in the relapse mouse model of Eric Nuermberger and Jacques Grosset at Johns Hopkins with support from the TB Alliance; the progression of TMC207 into late phase II and of OPC67683 into phase III; and the first new regimen EBA study, NC-001 also from the Alliance.

Read More →

November: Month of action on TB and maternal and child health

Target TB has joined up with the White Ribbon Alliance for Safe Motherhood (WRA) to raise awareness about the impact of tuberculosis (TB) on maternal and child health.

Read More →

New TB roadmap emphasizes critical role of research

“Elimination of tuberculosis (TB) is more than an aspiration. We know it could become a reality, but this will happen only if we achieve radical transformation in the way TB is diagnosed, treated and prevented. This goal can be realized only if TB research is intensified and envisioned in an entirely new way.” These are the first words of Lucica Ditiu, Executive Secretary of Stop TB Partnership, in the International Roadmap of Tuberculosis Research, launched this weekend in Lille.

Read More →

ZAMSTAR project reduces prevalence of tuberculosis by 22%

The results of a large-scale community-randomized trial, which were presented at the 42nd World Conference on Lung Health in Lille, France show that the Zambia South Africa TB and AIDS Reduction (ZAMSTAR) study's "Household Counselling" intervention reduced the prevalence of culture positive tuberculosis by 22% compared to the communities that did not receive the intervention.

Read More →

Out of the Dark: An implementers’ guide to managing TB in children

This report outlines the current state of paediatric TB care, looking at current practices, new developments and research needs – in paediatric TB diagnosis, treatment and prevention.

Read More →

Funding for TB research and development was flat in 2010 compared to 2009

New data released by the Treatment Action Group (TAG) and the Stop TB Partnership finds that in 2010 the world spent just $617 million in tuberculosis (TB) research and development (R&D), or 0.3% less than 2009 funding levels - the first time TAG documents no growth since it began tracking TB research investments in 2005.

Read More →

Page 79 of 81 · Total posts: 10

←First 78 79 80 Last→